When to Outsource vs Build a Laboratory
Outsourcing and building are not opposites. Most organizations end up with a deliberate mix — the skill is in choosing which work goes where.
Draft — owner to review
Companies weighing an in-house laboratory often frame the question as cost. Cost matters, but control, speed, expertise and risk usually decide it.
Signals that favor outsourcing
- Volume is low, irregular or uncertain.
- The method requires specialized instruments or expertise you would rarely use.
- Speed to first data matters more than long-run unit cost.
Signals that favor building
- Testing is core to your product or a competitive differentiator.
- Volume is high and predictable enough to keep capacity utilized.
- Turnaround or confidentiality requirements are difficult to contract for.
Outsourcing still carries responsibility
In FDA-regulated drug manufacturing, FDA guidance describes how owners and contract facilities should use written quality agreements to define responsibilities — the owner remains accountable for quality.[1]
When selecting contract testing laboratories, accreditation to ISO/IEC 17025 by an ILAC MRA signatory body offers one independent indicator of competence for the accredited scope.[2][3]
Advisor's analysis
Check the accredited scope, not just the certificate. A laboratory can be accredited for some methods and not the one you need.
A staged path
Many organizations outsource first, learn the method and volume profile, then bring the highest-volume or most strategic work in-house. That sequence reduces the risk of building capacity for demand that never arrives.
→ To source contract laboratories or issue an RFQ for testing services, see LaboratoryVortex.
Sources
- [1] U.S. Food and Drug Administration, “Contract Manufacturing Arrangements for Drugs: Quality Agreements — Guidance for Industry.”
- [2] International Organization for Standardization, “ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories.”
- [3] International Laboratory Accreditation Cooperation, “ILAC MRA and Signatories.”
Bracketed numbers link to sources. Passages labelled “Advisor's analysis” are interpretation, not cited fact.
Related advisory: Commercialization & Scientist to CEO · Strategic Partnerships & Alliances · FDA Regulatory & Quality Strategy
Scientific services and sourcing
Looking for laboratory capabilities or scientific services rather than a strategic advisory engagement? Explore Laboratory Vortex for sourcing and RFQs.
Explore Laboratory Vortex (opens in a new tab)These are separate destinations for different needs; links do not imply a formal affiliation, endorsement or Alliance membership.
More founder guides
- How to Start an Independent Testing Laboratory: Business and Accreditation Decisions
- How Laboratory Startups Can Evaluate Grants, Angels, Strategic Investors and Non-Dilutive Funding
- From Diagnostic Assay to Commercial Product: Validation, Regulatory Pathways, Reimbursement and Go-to-Market
- How to Build a Diagnostic Laboratory Partnership
